Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized open-label study of tislelizumab with investigational agents in first-line recurrent or metastatic head and neck squamous cell carcinoma
CTR20232123Phase 2Completed
- Sponsor
- BeOne Medicines
- Start
- Aug 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab, alcestobart, surzebiclimab in head and neck squamous cell carcinoma (HNSCC), sponsored by BeOne Medicines. Started Aug 2023; status: completed.
02
Drugs
tislelizumabalcestobartsurzebiclimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on CTR20232123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232123.